Literature DB >> 2017529

Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders?

J Elia1, B G Borcherding, J L Rapoport, C S Keysor.   

Abstract

The response to stimulant drugs of 48 boys with attention deficit/hyperactivity disorder was measured following dextroamphetamine, methylphenidate, and placebo in a double-blind crossover study. To distinguish lack of behavioral improvement from adverse drug effects, a day hospital setting and a wide dose range were used. Both drugs were highly and equally efficacious for the group as a whole, and frequently one drug or the other was superior for an individual child, or adverse effects occurred only on one of the stimulants. Only one of the 48 boys (2%) was discharged without the recommendation for continued stimulant drug treatment. "Nonresponse" appears to be extremely rare when both stimulants and a wide range of doses are given.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2017529     DOI: 10.1016/0165-1781(91)90126-a

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  53 in total

Review 1.  Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives.

Authors:  Roberta Russo; Mario Capasso; Paolo Paolucci; Achille Iolascon
Journal:  Eur J Clin Pharmacol       Date:  2010-11-11       Impact factor: 2.953

2.  D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD.

Authors:  Xueliang Fan; Ming Xu; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2009-10-22       Impact factor: 5.996

3.  Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials.

Authors:  Bjørn E Ramtvedt; Elisabeth Røinås; Henning S Aabech; Kjetil S Sundet
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05-09       Impact factor: 2.576

Review 4.  Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder.

Authors:  M Cyr; C S Brown
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

5.  Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder.

Authors:  Mark A Stein; Irwin Waldman; Jeffrey Newcorn; Jeffrey Bishop; Rick Kittles; Edwin H Cook
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05-09       Impact factor: 2.576

6.  Central Stimulant Treatment of Childhood Attention Deficit Hyperactivity Disorder : Issues and Recommendations from a US Perspective.

Authors:  D J Safer
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 7.  Genetic aspects in attention-deficit/hyperactivity disorder.

Authors:  O Albayrak; S Friedel; B G Schimmelmann; A Hinney; J Hebebrand
Journal:  J Neural Transm (Vienna)       Date:  2008-01-16       Impact factor: 3.575

Review 8.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 9.  Drug treatment for hyperactive children. Therapeutic guidelines.

Authors:  J Elia
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 10.  Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.

Authors:  Sharon B Wigal
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.